Methods to radiolabel somatostatin analogs with [18F]fluoride: current status, challenges, and progress in clinical applications

There is an ongoing interest of having a somatostatin analog radiotracer labeled with 18 F for PET imaging of neuroendocrine tumors. Nonetheless, there is none yet approved for clinical use. 18 F is the ideal radionuclide for PET imaging due to its high β + decay, suitable half-life and ease of prod...

Full description

Saved in:
Bibliographic Details
Published in:Journal of radioanalytical and nuclear chemistry 2020-12, Vol.326 (3), p.1519-1542
Main Authors: Pérez, David J., Ávila-Rodríguez, Miguel A.
Format: Article
Language:English
Subjects:
Chemistry
Chemistry and Materials Science
Diagnostic Radiology
Hadrons
Heavy Ions
Inorganic Chemistry
Nuclear Chemistry
Nuclear Physics
Physical Chemistry
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is an ongoing interest of having a somatostatin analog radiotracer labeled with 18 F for PET imaging of neuroendocrine tumors. Nonetheless, there is none yet approved for clinical use. 18 F is the ideal radionuclide for PET imaging due to its high β + decay, suitable half-life and ease of production. As with other peptides, the labeling of SSTA with 18 F comes along with its complications. In this review, we discuss the methods to label SSTA with 18 F highlighting the chemistry as well as an overview in the progress on preclinical and clinical applications of 18 F-labeled SSTA tracers.
ISSN:0236-5731
1588-2780
DOI:10.1007/s10967-020-07437-6